Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05946577
Other study ID # APHP230058
Secondary ID IDRCB 2022-A0268
Status Not yet recruiting
Phase
First received
Last updated
Start date July 2023
Est. completion date September 2026

Study information

Verified date July 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Florence HUGUET, MD, PhD
Phone 0033 (0) 1 56 01 62 10
Email Florence.huguet@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy


Description:

Radiotherapy with or without concomitant chemotherapy is the standard of care for patients diagnosed with locally advanced head and neck cancer. This treatment is associated with many side effects, especially tinnitus and hearing loss affecting patients' quality of life. Theses toxicities are due to chemotherapy and radiotherapy, with a synergic effect. The effects of chemoradiotherapy on hearing loss are already well documented but very limited data are available on the onset of tinnitus. Currently, no study established a correlation between tinnitus and hearing loss after treatment by chemoradiotherapy or exclusive radiotherapy. The main question we aim to answer is whether the development of tinnitus during treatment can be a precursor to hearing loss? Clinical data will be collected prospectively in 4 centers in Paris (Hôpital Tenon, Hôpital La Pitié-Salpêtrrière, Hôpital Saint-Louis and Hôpital Européen Georges Pompidou) to collect : - Patient data : - Birth date (age at diagnosis) - Tobacco use (active : yes/no, quantity in pack-year) - Alcohol use (active : yes/no, quantity in g/day) - Sex - Disease data : - Primitive site (oral cavity, nasopharynx, oropharynx, larynx, sinus, salivary gland, carcinoma with unknown primitive) - Histological type - HPV status - TNM stage - Data at diagnosis - Treatment data : - Post-operative situation (yes/no) - Radiotherapy dose received and number of fraction - Mean and max doses received in Gy on the right and left cochleas - Other otototoxic treatment taken during radiotherapy - Evaluation data : - Tinnitus evaluation (using SOMA-LENT criteria) - Audiogram with measures at 0,25, 0,5, 1, 2, 4, 6, 8, 10 and 12,5 kHz - Check for hearing "microloss" - If tinnitus present : acouphénométrie - If hearing aid fitting indication : APHAB (Abbreviated Profile of Hearing Aid Benefit) questionnaire


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 140
Est. completion date September 2026
Est. primary completion date June 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with locally advanced or post-operative ENT cancer with high risk of recurrence - Patient = 18 years - Absence of prior chemotherapy or radiotherapy - Patient eligible for chemotherapy with cisplatin according to the standard regimen: radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with chemotherapy with cisplatin 100 mg/m2 every 3 weeks (i.e. at week 1, 4 and 7) - Patient ineligible for cisplatin chemotherapy receiving: - Either exclusive radiotherapy (age > 70 years, contraindication: renal failure, patient wearing a device): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks. - either chemoradiotherapy with a chemotherapy protocol different from the standard scheme (due to a contraindication to cisplatin): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with non-standard chemotherapy ototoxic (cetuximab or carboplatin-5FU) Exclusion Criteria: - Tinnitus grade = 2 according to the SOMA-LENT scale - Patient fitted for hearing disorders - Significant cognitive disorders that may compromise the performance of the various assessments - Patients treated with weekly cisplatin - Patient's refusal to participate in research

Study Design


Locations

Country Name City State
France Radiotherapy Oncology Service TENON Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association between the onset of tinnitus and hearing loss at 3 months after treatment Evaluation of the tinnitus on each ear. Hearing loss is defined as a loss of more than 20 dB compared to the measurement made at inclusion 3 months after treatment
Secondary Tinnitus incidence According to Subjective, Objective, Management, Analytic- Late Effects Normal Tissue scales :SOMA-LENT scale (grade 1 to 4). at inclusion, at 3 weeks, at 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Hearing loss incidence audiogram with measures at 0,25, 0,5, 1, 2, 4, 6, 8, 10 and 12,5 kHz at inclusion, at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Association between the onset of tinnitus and/or hearing loss and quality of life Evaluation quality of life (Tinnitus Handicap Inventory) at inclusion, at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Association between the onset of tinnitus and/or hearing loss and quality of life Evaluation quality of life: EVA intensity and discomfort at inclusion, at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Association between the onset of tinnitus and/or hearing loss and quality of life Evaluation quality of life: EQ-5D-5L questionnaire at inclusion, at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Evolution of hearing disorders (tinnitus and/or hearing loss) using SOMA-LENT criteria and audiogram at inclusion, at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
Secondary Association between radiotherapy dose received on the cochlea and the onset of tinnitus mean dose and max dose 3 months after treatment
Secondary Association between radiotherapy dose received on the cochlea and hearing loss mean dose and max dose 3 months after treatment
Secondary Association between cisplatin dose received and the onset of tinnitus and/or hearing loss dose in mg/m2 3 months after treatment
Secondary Quality of life after hearing aid fitting in patients requiring hearing aid during/after treatment APHAB (Abbreviated Profile of Hearing Aid Benefit) questionnaire at 3 weeks, 6 weeks, 3 months after treatment, 6 months, 12 months and 18 months
See also
  Status Clinical Trial Phase
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Completed NCT00318890 - Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck Phase 1/Phase 2
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT06010381 - Muscle Energy Technique Versus Maitland Mobilization on Shoulder Pain and Disability N/A
Recruiting NCT06432998 - Perineal Massage in Women With Gynecological Cancer N/A
Completed NCT02714920 - DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD) N/A
Terminated NCT01910753 - Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population N/A
Completed NCT01194466 - Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC) N/A
Recruiting NCT03530033 - Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring N/A
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Recruiting NCT04750434 - PET MRI as a Staging Tool for Head and Neck Cancer
Withdrawn NCT05472506 - Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer Phase 1
Not yet recruiting NCT04261179 - Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer Phase 4
Completed NCT00723463 - Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue Phase 0
Recruiting NCT04673981 - Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA) N/A
Completed NCT05246891 - Rehabilitation Nursing Program in Otolaryngology
Completed NCT02738268 - Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients N/A
Recruiting NCT04722523 - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Phase 1
Completed NCT03245788 - Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study N/A